Merck (MRK) announced the FDA has approved Welireg – belzutifan -, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma – PPGL -. Pheochromocytoma and paraganglioma are rare tumors that come from the same tissue, but pheochromocytoma form in the adrenal gland and paraganglioma form outside the adrenal gland. These tumors can be caused by certain genetic syndromes or mutations. The approval is based on data from the single-arm LITESPARK-015 clinical trial, where the primary endpoint was objective response rate. Additional efficacy outcome measures included duration of response and time to response.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Bearish options flow identified in Merck (MRK), with shares down $-2.88 (-3.76%) near $73.75
- FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma
- Jefferies not seeing significant impact to Merck, Bristol from draft guidance
- UnitedHealth, Wayfair downgraded: Wall Street’s top analyst calls
- SCHD ETF News, 5/14/2025